Lataa...
Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy
The first US Food and Drug Administration (FDA)- and EMA-approved oncolytic virus has been available since 2015. However, there are no markers available that would predict benefit for the individual patient. During 2007–2012, we treated 290 patients with advanced chemotherapy-refractory cancers, usi...
Tallennettuna:
| Julkaisussa: | Mol Ther Oncolytics |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Gene & Cell Therapy
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6035494/ https://ncbi.nlm.nih.gov/pubmed/29989063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2018.04.003 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|